1. Generics Bulletin
  2. >>Business
  3. >>Deals

Another Denosumab Deal For mAbxience In MEA

MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets

 
• By Dave Wallace

A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”

View of Earth highlighting middle east and Africa
MS Pharma will market mAbxience’s denosumab in MEA territories • Source: Shutterstock

Spanish biosimilars developer mAbxience has struck an exclusive licensing deal with MS Pharma that will see the Jordan-based firm register and market mAbxience’s proposed denosumab biosimilar to Prolia/Xgeva rival in unspecified “select Middle East and Africa markets.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.